Trial Profile
An Exploratory, Pilot Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome: A Sub-study to the ZX008-1503 Open-Label Extension Trial
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Fenfluramine (Primary)
- Indications Dravet syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Zogenix
- 03 Jun 2051 Added age keywords, as inclusion criteria in NCT states- "Ages Eligible for Study: Child, Adult, Older Adult".
- 10 Nov 2023 Status changed from recruiting to discontinued.
- 15 Apr 2020 According to a Zogenix media release, the company will host an investor conference call in which Dr. Sullivan will discuss the updated interim analysis data from this trial.